Skip to main content

Table 4 Comparison between the serum level of neuron-specific enolase (NSE) and the clinical severity of stroke (NIHSS) among the patients (n = 37)

From: Validity of neuron-specific enolase as a prognostic tool in acute ischemic stroke in adults at Suez Canal University Hospital

  Total (n = 37) No-death (n = 31) Death (n = 6) Test of sig. p
NSE at presentation
 Mean ± SD 24.9 ± 8.8 23.1 ± 8.1 34.5 ± 6.2 U = 30.50* 0.007*
 Median (Min.–Max.) 27.8 (12.7–42.1) 26.7 (12.7–35.3) 36.6 (26.8–42.1)
NSE at 48 h
 Mean ± SD 24.0 ± 8.4 22.3 ± 7.7 33.0 ± 5.5 U = 27.0* 0.005*
 Median (Min.–Max.) 27.2 (11.6–41.0) 24.4 (11.6–33.5) 33.2 (25.7–41.0)
Zp1 0.002* 0.013* 0.046*   
NIHSS at presentation
 Moderate stroke (5–15) 15 (40.5%) 15 (48.4%) 0 (0.0%) χ2 = 4.883 FEp = 0.063
 Moderate to severe stroke (16–20) 17 (45.9%) 15 (48.4%) 2 (33.3%) χ2 = 0.459 FEp = 0.667
 Severe stroke ≥ 21 5 (13.5%) 1 (3.2%) 4 (66.7%) χ2 = 17.311* FEp = 0.001*
 Mean ± SD 16.4 ± 4.6 15.1 ± 3.5 23.5 ± 3.1 t = 5.517* < 0.001*
 Median (Min.–Max.) 16.0 (10.0–28.0) 16.0 (10.0–22.0) 24.0 (20.0–28.0)
NIHSS at 28 days
 Moderate stroke (5–15) 20 (54.1%) 20 (64.5%) 0 (0.0%) χ2 = 8.425* FEp = 0.005*
 Moderate to severe stroke (16–20) 11 (29.7%) 11 (35.5%) 0 (0.0%) χ2 = 3.030* FEp = 0.151
 Severe stroke ≥ 21 6 (16.2%) 0 (0.0%) 6 (100.0%) χ2 = 37.0* FEp < 0.001*
 Mean ± SD 15.6 ± 5.8 13.7 ± 3.8 25.7 ± 3.2 t = 7.152* < 0.001*
 Median (Min.–Max.) 14.0 (7.0–30.0) 13.0 (7.0–20.0) 26.0 (22.0–30.0)
tp1 0.008* < 0.001* 0.003*   
  1. χ2, chi-square test; FE, Fisher exact; t, Student’s t test; U, Mann-Whitney test; p, p value for comparing between the two studied groups; tp, p value for paired t test for comparing between two studied periods in each group and total; zp, p value for Wilcoxon signed-rank test for comparing between two studied periods in each group and total; NSE, neuron-specific enolase; NIHSS, National Institutes of Health Stroke Scale
  2. *Statistically significant at p ≤ 0.05